Tiprogrel

Phase 2Small molecule

TTianjin Institute of Pharmaceutical Research Co., Ltd

Tiprogrel is one of 4 small molecule programs targeting Cerebrovascular Event. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebrovascular EventRecruiting

Cerebrovascular EventPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Cerebrovascular Event

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 2

Aggrastat

MMedicure

Phase 3

1 3

Rhtnk-Tpa

CCSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.

Phase 3

2 4

Tiprogrel

TTianjin Institute of Pharmaceutical Research Co., Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Completed·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 1·NCT06584812·14 enrolled

Cerebrovascular Event1 trial

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Recruiting·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 2·NCT06601127·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tiprogrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tiprogrel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tiprogrel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Institute of Pharmaceutical Research Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTianjin Institute of Pharmaceutical Research Co., Ltd

Tiprogrel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Cerebrovascular Event1 trial

References

Drug Info

Quick Facts

Related News